DLL3-EXPRESSING TUMORS
Clinical trials for DLL3-EXPRESSING TUMORS explained in plain language.
Never miss a new study
Get alerted when new DLL3-EXPRESSING TUMORS trials appear
Sign up with your email to follow new studies for DLL3-EXPRESSING TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial targets rare and Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing an investigational drug called tarlatamab in adults with advanced cancers that have a specific protein called DLL3. The goal is to see if the drug is safe and can shrink these hard-to-treat tumors. Participants will receive the drug until their cancer worsen…
Matched conditions: DLL3-EXPRESSING TUMORS
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 06:56 UTC
-
New scan lights up Hard-to-Find cancer tumors
Diagnosis Recruiting nowThis study is testing a new type of PET scan designed to find neuroendocrine cancer tumors more accurately. The scan uses a special tracer that attaches to a protein called DLL3, which is often found on these cancer cells. Researchers will compare this new scan to standard imagin…
Matched conditions: DLL3-EXPRESSING TUMORS
Phase: NA • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Diagnosis
Last updated Apr 02, 2026 06:56 UTC